Evolus

Historical price data

Evolus is a commercial-stage biotech company with a mission to make the beauty experience accessible by offering high-quality aesthetic products at competitive price points. Its key achievement is establishing Jeuveau as the fastest-growing neurotoxin in the U.S. for four consecutive years and successfully launching the Evolysse dermal filler line. The company's strategy is to build a multi-product aesthetics portfolio by leveraging its commercial infrastructure, regulatory expertise, and direct sales force to in-license or acquire additional products, targeting a broad provider network of dermatologists, plastic surgeons, and medical spas.

Proprietary manufacturing and purification processes for protein-based injectables, including a 900 kDa botulinum toxin complex (Jeuveau) and Cold-X™ technology for hyaluronic acid dermal fillers (Evolysse).

Evolus competes in the crowded medical aesthetics market against dominant players AbbVie (Botox, Juvéderm) and Galderma (Dysport, Restylane), as well as Merz and Revance. Its position as a value-focused challenger relies on competitive pricing, aggressive marketing, and innovative loyalty programs to capture share from established brands.